Porch Group Appoints John Campbell as Vice President of Investor Relations
SEATTLE--(BUSINESS WIRE)--Porch Group, Inc. ('Porch' or 'the Company') (NASDAQ: PRCH), a new kind of homeowners insurance company, today announced the appointment of John Campbell as VP of Investor Relations, effective June 9, 2025.
John will report to Shawn Tabak, Chief Financial Officer, and will be responsible for leading Porch's engagement with investors and analysts, providing insights into Porch's financial performance and strategic direction.
John brings 14 years of sell-side experience. Prior to joining Porch, John served as Managing Director at Stephens Inc where he led coverage of real estate-related stocks.
'We are thrilled to welcome John to Porch,' said Shawn Tabak, Chief Financial Officer. 'His extensive capital markets experience and deep relationships with investors will be valuable as we continue to execute our strategic initiatives and communicate our growth story to the market. John has been covering Porch over the last several years and knows our business well. We are excited to have him join at the start of this next exciting chapter in our company's journey.'
'Porch has long stood out to me as having the ability to structurally change the home ownership lifecycle, and, with each passing day, I feel that the Company takes a step forward in capitalizing on that truly unique opportunity,' said John Campbell. 'I could not be more excited to join the team and do my part in helping drive the business to new heights while also clearly articulating the strategy to the investment community along the way.'
About Porch Group
Porch Group, Inc. ('Porch') is a new kind of homeowners insurance company. Porch's strategy to win in homeowners insurance is to deploy leading vertical software solutions in select home-related industries, provide the best services for homebuyers including important moving services, leverage unique data for advantaged underwriting, and provide more protection for policyholders. To learn more about Porch, visit ir.porchgroup.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform rating on the stock but cut the price target to $420 from $423. The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company's next-generation cystic fibrosis treatment, Alyftrek. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. RBC Capital remains concerned about the gradual conversion compared to consensus expectations. Consequently, it has warned it could affect the company's operating margins by up to 2%. Nevertheless, the research firm insists that the company's cystic fibrosis franchise remains well-insulated from sector headwinds. However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current valuation in the market. Consequently, its reduced price target reflects lower year Alyftrek conversion rates. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops and commercializes therapies for serious diseases. They are known for their work in cystic fibrosis (CF) and are expanding into other areas like cell and genetic therapies. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
Incyte Corporation (NASDAQ:INCY) is one of the 10 biotech stocks screaming a buy. On June 17, Incyte was a big mover in the market, announcing the signing of a strategic partnership with Netherlands QIAGEN N.V. QGEN. The two are coming together to enhance the development of a novel diagnostic panel to support investigational treatments for myeloproliferative neoplasms (MPNs). A researcher in a lab coat working with a microscope, studying a biopharmaceutical drug. The strategic partnership covers the development of Incyte's investigational monoclonal antibody targeting mutant calreticulin (mutCALR), currently under development for myelofibrosis (MF) and essential thrombocythemia (ET). The deal is also expected to benefit Incyte in advancing its precision medicine efforts in MPNs. Under the terms of the agreement, QIAGEN is to develop a multimodal panel using next-generation sequencing (NGS) technology. The panel aims to identify key gene alterations in MPNs. The panel will also be validated on the Illumina NextSeq 550Dx platform for use with whole blood samples. Incyte Corporation (NASDAQ:INCY) is a global biopharmaceutical company that focuses on discovering, developing, and commercializing proprietary therapeutics for patients with unmet medical needs. It develops drugs for rare and hard-to-treat diseases, including those in oncology and inflammation/autoimmunity. While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
37 minutes ago
- Yahoo
Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches
PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the 10 biotech stocks screaming a buy. On June 17, analysts at Truist Securities initiated coverage of the stock with a 'Buy' rating and an $80 price target. The research firm remains bullish about the company's prospects ahead of the launch of two key drugs. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The research firm expects the two new drugs to act as catalysts for the biopharmaceutical company. The two drugs are sapropterin for phenylketonuria (PKU) and vatiquinone for Friedreich's ataxia (FA). The two drugs are slated for release in July and August, respectively. Truist Securities expects the two drugs to generate more than $2 billion in peak sales, which makes it believe the stock is undervalued at current levels. In addition to the two drugs, the research firm has echoed PTC Therapeutics' promising pipeline, especially PTC518, for Huntington's disease. Consequently, Truist Securities expects the launch of two new drugs and the development of the pipeline to help offset concerns related to Translarna's (ataluren) performance in Duchenne muscular dystrophy (DMD). PTC Therapeutics, Inc. (NASDAQ:PTCT) is a global biopharmaceutical company focused on developing and commercializing therapies for rare diseases. It discovers and develops treatments that benefit patients with unmet medical needs, particularly in para-genetic disorders. While we acknowledge the potential of PTCT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
